Patent intelligence · CA
CA 2890920
DERIVES DE 1,3-DIHYDROIMIDAZOLE-2-THIONE UTILISABLES DANS LE TRAITEMENT DE L'HYPERTENSION ARTERIELLE PULMONAIRE ET DES LESIONS PULMONAIRES
DERIVES DE 1,3-DIHYDROIMIDAZOLE-2-THIONE UTILISABLES DANS LE TRAITEMENT DE L'HYPERTENSION ARTERIELLE PULMONAIRE ET DES LESIONS PULMONAIRES
Patent details — CA 2890920
- Jurisdiction
- CA
- Status
- granted
- Grant date
- May 22, 2014
- Expiration
- May 17, 2034
- Applicant
- BIAL PORTELA & Cª S A [PT]
- CPC classes
- A61K 31/ 417 A I, A61K 31/ 4178 A I, A61K/31417, A61K/314178
Quick answer
CA 2890920 (DERIVES DE 1,3-DIHYDROIMIDAZOLE-2-THIONE UTILISABLES DANS LE TRAITEMENT DE L'HYPERTENSION ARTERIELLE PULMONAIRE ET DES LESIONS PULMONAIRES) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted May 22, 2014. Expires May 17, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIAL PORTELA & Cª S A [PT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 417 A I, A61K 31/ 4178 A I, A61K/31417, A61K/314178, A61P 9/ 10 A I, A61P 9/ 12 A I
More from BIAL PORTELA & Cª S A [PT]
Related pharmaceutical patents in our USPTO index.
-
WO 2022081033
OPICAPONE ET LÉVODOPA POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
granted -
WO 2022025781
DISPERSION SOLIDE D'OPICAPONE
granted -
WO 2021182981
OPICAPONE MICRONISÉE
granted -
WO 2020246903
INHIBITEURS DE DOPAMINE-B-HYDROXYLASE
granted -
AU 2018379646
Dopamine-B-hydroxylase inhibitors
granted -
BR PI0923819
compostos farmacêuticos
granted -
EP 3515433
DIE BLUT-HIRN-SCHRANKE PASSIERENDE DOPAMIN-B-HYDROXYLASE-INHIBITOREN
granted -
US 2019008774
PHARMACEUTICAL FORMULATIONS COMPRISING NITROCATECHOL DERIVATIVES AND METHODS OF MAKING THE SAME
granted
Frequently asked questions
What is US patent 2890920?
CA 2890920 (DERIVES DE 1,3-DIHYDROIMIDAZOLE-2-THIONE UTILISABLES DANS LE TRAITEMENT DE L'HYPERTENSION ARTERIELLE PULMONAIRE ET DES LESIONS PULMONAIRES) is held by BIAL PORTELA & Cª S A [PT]. Status: granted. Granted May 22, 2014. Expires May 17, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 2890920?
BIAL PORTELA & Cª S A [PT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does CA 2890920 expire?
Our index shows an expiration date of May 17, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.